Knudsen F U
Acta Neurol Scand Suppl. 1991;135:1-24.
Major cohort studies document that the long-term prognosis for most children with febrile convulsions (FC) is excellent. The 2 main treatment alternatives so far have been long-term prophylaxis with phenobarbital or valproate or no prophylaxis at all. Phenobarbital at times of fever is ineffective and obsolete. Consensus has emerged that long-term prophylaxis with antiepileptic drugs is rarely justified in FC considering the side effects and the favourable prognosis. No treatment at all does not appear quite satisfactory either, as FC have a high recurrence rate, disrupt family life and may have emotional consequences for the family. Moreover, all FC children face a risk, although admittedly low, of subsequent long-lasting potentially central nervous system (CNS)-damaging seizures. However, 2 further options exist: treatment with rapid-acting benzodiazepines solely at times of greatest risk, i.e., at high fever or at renewed seizures. Several clinical trials have confirmed that intermittent diazepam prophylaxis by way of a few doses of the drug per year provides effective seizure control and reduces the recurrence rate by one half or two thirds. The treatment is feasible and cheap, well tolerated by the child and well accepted by the parents. Compliance problems are common and only partly abatable. Trivial side effects are frequent. Transient respiratory apnoea does occur, but 15 years' experience substantiates that serious side effects are remarkably rare. Acute anticonvulsant treatment with rectal diazepam in solution given by the parents to stop ongoing seizures and to prevent immediate recurrences is an attractive alternative. It is feasible, is probably effective and minimizes the use of drugs, but compliance problems are common and protracted seizures are not always controlled. The subsequent management should include a risk profile approach considering a combination of risk factors for new FC rather than a single factor. By means of a risk index, based on simple clinical data including age at onset, family seizure history, seizure type and frequency of fever, children may be identified as being at low, intermediate or high risk for further febrile fits. However, risk factors for new FC and not for subsequent epilepsy should be used. It is concluded that preventing or abbreviating new FC with benzodiazepines appears to be a useful, although not ideal, drug-minimizing approach in managing many children with simple or complex FC. From a health hazard viewpoint, treatment is not strictly mandatory, although advisable. A selective strategy seems rational. Intermittent diazepam prophylaxis may preferably be offered to children at high risk for new FC.(ABSTRACT TRUNCATED AT 400 WORDS)
大型队列研究表明,大多数热性惊厥(FC)儿童的长期预后良好。到目前为止,两种主要的治疗选择是用苯巴比妥或丙戊酸进行长期预防,或者根本不进行预防。发热时使用苯巴比妥无效且过时。考虑到副作用和良好的预后,对于FC患儿,已达成共识:长期使用抗癫痫药物预防很少有必要。完全不治疗似乎也不太令人满意,因为FC复发率高,会扰乱家庭生活,可能给家庭带来情感影响。此外,所有FC患儿都面临后续发生可能对中枢神经系统(CNS)造成长期损害的癫痫发作的风险,尽管这种风险公认较低。然而,还有另外两种选择:仅在风险最高时,即高热或再次发作时,使用速效苯二氮䓬类药物进行治疗。多项临床试验证实,每年通过服用几剂地西泮进行间歇性预防,可有效控制癫痫发作,并将复发率降低一半或三分之二。这种治疗方法可行且费用低廉,患儿耐受性良好,家长也容易接受。依从性问题很常见,且只能部分缓解。轻微副作用很频繁。短暂性呼吸暂停确实会发生,但15年的经验证实,严重副作用非常罕见。由家长给患儿直肠给予地西泮溶液进行急性抗惊厥治疗,以终止正在发作的癫痫并预防立即复发,是一种有吸引力的替代方法。它可行,可能有效,且能尽量减少药物使用,但依从性问题很常见,持续性癫痫发作并不总是能得到控制。后续管理应采用风险评估方法,考虑多种新发性FC的风险因素组合,而不是单一因素。通过基于包括发病年龄、家族癫痫病史、癫痫发作类型和发热频率等简单临床数据的风险指数,可以将儿童识别为进一步热性惊厥发作的低、中或高风险人群。然而,应使用的是新发性FC的风险因素,而非后续癫痫的风险因素。结论是,在管理许多单纯性或复杂性FC患儿时,用苯二氮䓬类药物预防或缩短新发性FC发作似乎是一种有用的、尽管并不理想的尽量减少药物使用的方法。从健康危害的角度来看,虽然建议进行治疗,但并非严格强制。选择性策略似乎是合理的。间歇性地西泮预防可能最好提供给新发性FC高风险的儿童。(摘要截断于400字)